Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity
Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity GlobeNewswire August 13, 2025 This is the first ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune disease The Phase 1/2 study (up to 141 participants) will evaluate the safety, […]